Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 04, 2015 5:28 AM ET


Company Overview of Sound Pharmaceuticals, Inc.

Company Overview

Sound Pharmaceuticals, Inc., a biopharmaceutical company, develops prescription drugs that enable doctors and patients to prevent and treat hearing loss. It focuses on developing drug treatments for sensori-neural hearing loss. Sound Pharmaceuticals, Inc. was incorporated in 2001 and is based in Seattle, Washington.

4010 Stone Way North

Suite 120

Seattle, WA 98103

United States

Founded in 2001





Key Executives for Sound Pharmaceuticals, Inc.

President and Director
Chief Medical Officer
Compensation as of Fiscal Year 2015.

Sound Pharmaceuticals, Inc. Key Developments

Sound Pharmaceuticals, Inc. Submits Phase 2 Clinical Trial Data on SPI-1005 for the Prevention and Treatment of Sensorineural Hearing Loss

Sound Pharmaceuticals has submitted a scientific abstract for presentation at the American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting in Orlando FL. The Phase 2 clinical trial enrolled 83 subjects with normal hearing or slight hearing loss in an iPod(R) music protocol that induces a slight but temporary hearing loss or threshold shift (TTS). Subjects were randomized in a double-blinded manner to either placebo or three different dosages of SPI-1005 and treated before, during, and after the music exposure. Repeated hearing tests were conducted to determine the incidence, severity and duration of the TTS over the course of one week. The data indicate that SPI-1005 treatment dramatically reduced the incidence, severity and duration of the TTS induced by loud sound vs placebo controls. In addition, all doses of SPI-1005 were well tolerated with no observed or reported adverse events related to study drug. SPI-1005 is an oral capsule that contains ebselen, a novel molecule that mimics and induces the activity of Glutathione Peroxidase, a critical enzyme in the inner ear that protects it from damage caused by loud sounds or noise. In preclinical studies, ebselen treatment was shown to reduce the TTS and permanent threshold shift caused by intense noise exposure or ototoxic drug exposure such as cancer chemotherapy.

Sound Pharmaceuticals Completes its First Phase 2 Clinical Trial with SPI-1005 Involving iPod or Noise Induced Hearing Loss

Sound Pharmaceuticals has successfully completed enrollment of its Phase 2 clinical trial with SPI-1005 at the University of Florida. This study enrolled 80 healthy subjects with normal or slight hearing loss and exposed the volunteer to calibrated music using an iPod(R) and insert earphones. The sound level was established based on prior human studies where a slight temporary auditory threshold shift (TTS) was safely induced. The listeners were randomized to either placebo or SPI-1005 and treated before and after music exposure. The level of TTS was determined at several time points after the music exposure and all subjects and investigators were blinded to the intervention. SPI-1005 is an oral capsule that contains ebselen, a synthetic molecule that mimics and induces the activity of Glutathione Peroxidase (GPx), a critical enzyme in the inner ear that protects it from damage caused by loud sounds or noise. In preclinical studies, ebselen treatment was shown to improve GPx levels within critical cochlear structures thereby reducing the TTS induced by intense noise. Ebselen is also under clinical investigation for chemotherapy induced ototoxicity in adult cancer patients, a disease that involves both hearing loss and tinnitus.

Similar Private Companies By Industry

Company Name Region
Abraxis Health, Inc. United States
Cangene bioPharma, Inc. United States
Carmot Therapeutics, Inc. United States
GlaxoSmithKline Holdings (Americas) Inc. United States
Honey Naturals LLC United States

Recent Private Companies Transactions

Private Placement
August 7, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sound Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at